Trials / Recruiting
RecruitingNCT05254782
Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 360 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Conditions
Timeline
- Start date
- 2021-07-06
- Primary completion
- 2026-03-30
- Completion
- 2027-03-30
- First posted
- 2022-02-24
- Last updated
- 2024-12-06
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT05254782. Inclusion in this directory is not an endorsement.